DDInter1676 DDInter1000
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or
Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023.
Ivosidenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Ivosidenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Ivosidenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Ivosidenib {u} may lead to a major life threatening interaction when taken with {v} Alfuzosin
Ivosidenib {u} may lead to a major life threatening interaction when taken with {v} Oliceridine
Ivosidenib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Ivosidenib may lead to a major life threatening interaction when taken with Alfuzosin
Ivosidenib may lead to a major life threatening interaction when taken with Oliceridine